Dec. 7, 2022

Qurgen received FDA approval for the Phase I clinical trial IND (IND Number: 152226) for SON-DP, a transcription factor-based anti-tumor drug indicated for breast cancer, pancreatic cancer, ovarian cancer, and colorectal cancer.